MRI-based habitat radiomics for preoperative prediction of axillary pathological complete response in breast cancer after neoadjuvant therapy: a multicenter study - Top-Institutions - MDSpire

MRI-based habitat radiomics for preoperative prediction of axillary pathological complete response in breast cancer after neoadjuvant therapy: a multicenter study

  • By

  • Lei Ma

  • Shunian Li

  • Ziwei Cao

  • Jun Liao

  • Mengting Xu

  • Chuanjian Lv

  • Chunmiao Xu

  • Hongna Tan

  • May 13, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Henan Provincial People’s Hospital
    Henan Provincial People’s Hospital

    Zhengzhou, Henan

    Key Differentiators

    • Oncology

  • #2

    Henan Cancer Hospital
    Henan Cancer Hospital

    Zhengzhou, Henan

    Key Differentiators

    • Oncology

  • #3

    Sun Yat-sen University Cancer Center
    Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong

    Key Differentiators

    • Oncology

  • #4

    Chuiyangliu Hospital affiliated with Tsinghua University
    Chuiyangliu Hospital affiliated with Tsinghua University

    Beijing, Beijing

    Key Differentiators

    • Oncology

  • #5

    Maastricht University Medical Centre+
    Maastricht University Medical Centre+

    Maastricht, Limburg

    Key Differentiators

    • Oncology

Original Source(s)

MRI-based habitat radiomics for preoperative prediction of axillary pathological complete response in breast cancer after neoadjuvant therapy: a multicenter study

  • by Lei Ma, Shunian Li, Ziwei Cao, Jun Liao, Mengting Xu, Chuanjian Lv, Chunmiao Xu, Hongna Tan

  • May 13, 2026

Related Content

Retraction: MicroRNA-935 directly targets FZD6 to inhibit the proliferation of human glioblastoma and correlate to glioma malignancy and prognosis

  • May 28, 2026

Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer

Management of toxicities from antibody – drug conjugates in breast cancer